Form 4: Biogen Director Caroline Dorsa Reports Acquisition of Common Stock
SEC Filing
Director Caroline Dorsa reported acquiring 1,785 shares of Biogen Inc. common stock on June 21, 2024.
Summary
- On June 21, 2024, Caroline Dorsa, a director at Biogen Inc., acquired 1,785 shares of common stock.
- The acquisition was a direct transaction.
- Following the transaction, Ms. Dorsa beneficially owns 26,607 shares of Biogen Inc. common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing. The director's stock purchase is a mildly positive signal, but not significantly impactful on its own.
Positives
- A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. This filing indicates a director's recent stock acquisition, which is a common occurrence.
Stakeholder Impact
- Shareholders may view the director's stock purchase as a positive sign of confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of transaction: Caroline Dorsa acquired 1,785 shares of Biogen Inc. common stock. |
| 06/25/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.